OUTLINE
1. Immutep TACTI-002 and INSIGHT Clinical Results & Update
2. Notice: Forward Looking Statements
3. Overview
4. LAG-3 Overview & Product Candidates
5. LAG-3 Pioneer: French immunologist Frédéric Triebel, PhD, MD, Immutep CMO & CSO
6. Acceleration in the LAG-3 Space
7. LAG-3 Therapeutic Landscape Overview
8. Immutep Mission: Targeting LAG-3 / MHC II. Multiple product candidates in numerous diseases
9. MHC II / LAG-3 Interaction as a Therapeutic Target
10. Eftilagimod Alpha (efti or IMP321)
11. Efti: an Innovative LAG-3 I-O Product Candidate
12. Efti: Potential Pipeline in a Product. Potential for use in various combination settings
13. Clinical Development . Efti: Main Trials*
14. Combining efti and anti-PD-1 pembrolizumab TACTI-002
15. APC activator – ICI combinations
16. TACTI-002 (Phase II). Design & Status
17. TACTI-002 (Phase II). Safety
18. Non-Small Cell Lung Cancer (NSCLC). Introduction
19. TACTI-002 Results(1). 1st line NSCLC (Part A)
20. TACTI-002 Results(1). 1st line NSCLC (Part A)
21. TACTI-002 Results(1). 1st line NSCLC (Part A) - Benchmarking
22. Head & Neck Squamous Cell Carcinoma (HNSCC). Introduction
23. TACTI-002 Results(1). 2nd line HNSCC (Part C)
24. TACTI-002 Results(1). 2nd line HNSCC (Part C)
25. TACTI-002 Results(1). 2nd line HNSCC (Part C)
26. TACTI-002 Results(1). 2nd line HNSCC (Part C) – Benchmarking
27. Combining efti and anti-PD-L1 avelumab. INSIGHT-004
28. INSIGHT Platform Trial in Solid Tumours. INSIGHT-004: Efti + Avelumab Combination
29. INSIGHT-004 (Stratum-D). Results(1)
30. Competition
31. Eftilagimod Alpha. Leader in its Class of Oncology Products
32. Summary and Outlook
33. TACTI-003 Trial in 1st line HNSCC. 1st line HNSCC SoC
34. TACTI-003 Trial in 1st line HNSCC. Current Design + Status
35. INSIGHT Platform Trial in Solid Tumours. Stratum-005: Efti + Bintrafusp Alfa Combination
36. 2020 & 2021 News Flow*
37. Summary
38. Thank you. Q&A
0000000000000000